A single dose, three-arm, placebo-controlled, phase I study of the bradykinin B2 receptor antagonist Anatibant (LF16-0687Ms) in patients with severe traumatic brain injury (Q46869499)
Jump to navigation
Jump to search
scientific article published in December 2005
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A single dose, three-arm, placebo-controlled, phase I study of the bradykinin B2 receptor antagonist Anatibant (LF16-0687Ms) in patients with severe traumatic brain injury |
scientific article published in December 2005 |
Statements
1 reference
A single dose, three-arm, placebo-controlled, phase I study of the bradykinin B2 receptor antagonist Anatibant (LF16-0687Ms) in patients with severe traumatic brain injury (English)
1 reference
Anthony Marmarou
1 reference
Martine Guy
1 reference
Laine Murphey
1 reference
Francis Roy
1 reference
Laure Layani
1 reference
Jean-Philippe Combal
1 reference
Claude Marquer
1 reference
American Brain Injury Consortium
1 reference
1 December 2005
1 reference
1 reference
22
1 reference
1444-1455
1 reference
12
1 reference
Identifiers
1 reference
1 reference